|
1
|
Carmeliet P and Jain RK: Angiogenesis in
cancer and other diseases. Nature. 407:249–257. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Folkman J: Tumor angiogenesis. Adv Cancer
Res. 43:175–203. 1985. View Article : Google Scholar
|
|
3
|
Folkman J, Watson K, Ingber D and Hanahan
D: Induction of angiogenesis during the transition from hyperplasia
to neoplasia. Nature. 339:58–61. 1989. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bellen JA, Van Diest PJ and Baak JP:
Relationships between vascularization and proliferation in invasive
breast cancer. J Pathol. 189:309–318. 1999. View Article : Google Scholar
|
|
5
|
Li CY, Shan S, Huang Q, Braun RD, Lanzen
J, Hu K, Lin P and Dewhirst MW: Initial stages of tumor
cell-induced angiogenesis: evaluation via skin window chambers in
rodent models. J Natl Cancer Inst. 92:143–147. 2000. View Article : Google Scholar
|
|
6
|
de Vries C, Escobedo JA, Ueno H, Houck K,
Ferrara N and William LT: The fms-like tyrosine kinase, a receptor
for vascular endothelial growth factor. Science. 255:989–991.
1992.
|
|
7
|
Millauer B, Wizigmann-Voos S, Schnurch H,
Martinez R, Møller NP, Risau W and Ullrich A: High affinity VEGF
binding and developmental expression suggest Flk-1 as a major
regulator of vasculogenesis and angiogenesis. Cell. 72:835–846.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mazure NM, Chen EY, Laderoute KR and
Giaccia AJ: Induction of vascular endothelial growth factor by
hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt
signaling pathway in Ha-ras-transformed cells through a hypoxia
inducible factor-1 transcriptional element. Blood. 90:3322–3331.
1997.
|
|
9
|
Bolat F, Kayaselcuk F, Nursal TZ,
Yagmurdur MC, Bal N and Demirhan B: Microvessel density, VEGF
expression, and tumor-associated macrophages in breast tumors:
correlations with prognostic parameters. J Exp Clin Cancer Res.
25:365–372. 2006.PubMed/NCBI
|
|
10
|
Holash J, Maisonpierre PC, Compton D,
Boland P, Alexander CR, Zagzag D, Yancopoulos GD and Wiegand SJ:
Vessel cooption, regression, and growth in tumors mediated by
angiopoietins and VEGF. Science. 284:1994–1998. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yancopoulos GD, Davis S, Gale NW, Rudge
JS, Wiegand SJ and Holash J: Vascular-specific growth factors and
blood vessel formation. Nature. 407:242–248. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ikeda E, Achen MG, Breier G and Risau W:
Hypoxia-induced transcriptional activation and increased mRNA
stability of vascular endothelial growth factor in C6 glioma cells.
J Biol Chem. 270:19761–19766. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Forsythe JA, Jiang BH, Iyer NV, Agani F,
Leung SW, Koos RD and Semenza GL: Activation of vascular
endothelial growth factor gene transcription by hypoxia-inducible
factor 1. Mol Cell Biol. 16:4604–4613. 1996.PubMed/NCBI
|
|
14
|
Levy NS, Goldberg MA and Levy AP:
Sequencing of the human vascular endothelial growth factor (VEGF)
3′ untranslated region (UTR): conservation of five
hypoxia-inducible RNA-protein binding sites. Biochem Biophys Acta.
1352:167–173. 1997.
|
|
15
|
Shima DT, Kuroki M, Deutsch U, Ng YS,
Adamis AP and D’Amore PA: The mouse gene for vascular endothelial
growth factor. Genomic structure, definition of the transcriptional
unit, and characterization of transcriptional and
post-transcriptional regulatory sequences. J Biol Chem.
271:3877–3883. 1996.
|
|
16
|
Fukumura D, Xu L, Chen Y, Gohongi T, Seed
B and Jain RK: Hypoxia and acidosis independently up-regulate
vascular endothelial growth factor transcription in brain tumors in
vivo. Cancer Res. 61:6020–6024. 2001.PubMed/NCBI
|
|
17
|
Melillo G, Taylor LS, Brooks A, Musso T,
Cox GW and Varesio L: Functional requirement of the
hypoxia-responsive element in the activation of the inducible
nitric oxide synthase promoter by the iron chelator
desferrioxamine. J Biol Chem. 272:12236–12243. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang GL and Semenza GL: Desferrioxamine
induces erythropoietin gene expression and hypoxia-inducible factor
1 DNA-binding activity: implications for models of hypoxia signal
transduction. Blood. 82:3610–3615. 1993.PubMed/NCBI
|
|
19
|
Potier E, Ferreira E, Dennler S, Mauviel
A, Oudina K, Logeart-Avramoglou D and Petite H:
Desferrioxamine-driven upregulation of angiogenic factor expression
by human bone marrow stromal cells. J Tissue Eng Regen Med.
2:272–278. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Koshikawa N, Takenaga K, Tagawa M and
Sakiyama S: Therapeutic efficacy of the suicide gene driven by the
promoter of vascular endothelial growth factor gene against hypoxic
tumor cells. Cancer Res. 60:2936–2941. 2000.PubMed/NCBI
|
|
21
|
Liu LZ, Hu XW, Xia C, He J, Zhou Q, Shi X,
Fang J and Jiang BH: Reactive oxygen species regulate epidermal
growth factor-induced vascular endothelial growth factor and
hypoxia-inducible factor-1α expression through activation of AKT
and P70S6K1 in human ovarian cancer cells. Free Radic Biol Med.
41:1521–1533. 2006.PubMed/NCBI
|
|
22
|
Roybal CN, Hunsaker LA, Barbash O, Vander
Jagt DL and Abcouwer SF: The oxidative stressor arsenite activates
vascular endothelial growth factor mRNA transcription by an
ATF4-dependent mechanism. J Biol Chem. 280:20331–20339. 2005.
View Article : Google Scholar
|
|
23
|
Jung YD, Nakano K, Liu W, Gallick GE and
Ellis LM: Extracellular signal-regulated kinase activation is
required for up-regulation of vascular endothelial growth factor by
serum starvation in human colon carcinoma cells. Cancer Res.
59:4804–4807. 1999.
|
